GREY:IPHAF - Post by User
Post by
ngerritson Aug 07, 2010 8:53pm
557 Views
Post# 17331153
Lux buying ISA
Lux buying ISA
It is becoming evident that CEO Mitchell (Lux) should buy ISA:
FDA approval triggers $7M payment to ISA.
EMA approval triggers $3.5 payment to ISA
total if both approved = $10.5M or
.08 per share.
Lux would avoid paying any royalty to ISA aswell and have a public listing. A BIG THING.
I guess the question is will Palidan sell? they seem to be content on using the tax benefits of ISA and not give a s__T on what else happens. You would think they would like to see fda approval and therefore use there marketing expertise to help Lux get doctors prescriping vocsporin.
This thing just boggles my mind. no negotiating leverage whatsoever.